Full Text
Breakthrough Therapy status – expedited FDA regulatory approval but what about the payers?

Abstract

Authors

R. Macaulay P. Cost

Back to Volume 18, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×